Metagenomi Therapeutics, Inc.

MGXNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$25.2M

▼ 51.8% YoY

Net Income

-$87.9M

▼ 12.6% YoY

EPS

$-2.36

0.0% YoY

Cash

$41.7M

▲ 52.3% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.